DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: October 21, 2026: 9:15 a.m. – 1:30 p.m. (Central Time)
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2380

Attendance

- Members in attendance: Jacques Beasley; Mary Mescher Benbenek, PhD, APRN; Jeannine Conway, PharmD; Tenzin Dadon, MN; Emily Jaeger, PharmD; Emma Ryan, PharmD; Kelly Ruby, PharmD; Jena Wirt, DO
- Members absent: Katherine Montag Schafer, PharmD; Sandra Widhalm Murphy, RPh; Sheila Scheuer, PharmD; Romie Tinsay, MD;
- DHS staff present: Nathan Chomilo, MD; Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Aaron Drake, RPh; Erin Neumann, PharmD
- Others in attendance: Naana Osei-Boateng, PharmD; Chloe Groomes, PharmD; Andrew Wherley, PharmD; Laura Pounders, PharmD

Report of the Chair

- Kelly Ruby presided over the meeting.

Approval of Minutes

- The DFC approved the minutes from the July 2026 meeting with the following amendment: classes reviewed under the consent agenda umbrella to be listed in the minutes.

DHS Housekeeping

- The department has an actual acquisition cost survey in progress. It is mandatory for all pharmacies to participate in the survey; and all in attendance are encouraged to help share this information.

Old Business

- None

New Business:

Specialty Drugs for Continued PA

- The committee discussed Lyfgenia and recommended to DHS by a unanimous vote that Lyfgenia remain on PA with the proposed criteria.

- The committee discussed Kygevvi and recommended to DHS by a unanimous vote that Kygevvi remain on PA with the proposed criteria.

- The committee discussed Loargys and recommended to DHS by a unanimous vote that Loargys remain on PA with the proposed criteria.

- The committee discussed Yuviwel and recommended to DHS by a unanimous vote that Yuviwel remain on PA with the proposed criteria.

- The committee discussed Avlayah and recommended to DHS by a unanimous vote that Avlayah remain on PA with the following amendments to the proposed criteria:
    - Initial approval criteria, bullet point #3, be modified to: "Documented baseline age-appropriate and developmentally appropriate assessments selected by the treating MPS specialist.
    - Renewal criteria, bullet point #2, be modified to: "Patient has demonstrated a beneficial response to therapy compared to pretreatment age-appropriate and developmentally appropriate baseline values assessments selected by the treating MPS specialist; AND…

- The committee discussed Baxfendy and recommended to DHS by a unanimous vote that Baxfendy remain on PA with the proposed criteria.

- The committee discussed Hepcludex and recommended to DHS by a unanimous vote that Hepcludex Preferred Drug List (PDL) Review

DISCUSSION ITEMS:

- The committee discussed the Angiotensin Modulator Combinations therapeutic class and recommended the following to the department by a unanimous vote:
    - WIDAPLIK (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Angiotensin Modulators therapeutic class and recommended the following to the department by a unanimous vote:
    - TELMISARTAN (ORAL) and TELMISARTAN HCTZ (ORAL) to be moved on the PDL to PREFERRED.
    - MOEXIPRIL (ORAL) to be moved on the PDL to NONPREFERRED.
    - AZILSARTAN (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Antiemetic/Antivertigo Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - ONDANSETRON ODT 4 MG, 8 MG (ORAL) to be added to the PDL as PREFERRED

- SCOPOLAMINE (TRANSDERM) to be moved on the PDL to PREFERRED.
- TRANSDERM-SCOP (TRANSDERM) to be moved on the PDL to NONPREFERRED.
- NEREUS CAPSULE (ORAL) and ONDANSETRON ODT 16 MG to be added to the PDL as NONPREFERRED.

- The committee discussed the Antifungals, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - ECONAZOLE NITRATE FOAM (ECOZA) (TOPICAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Calcium Channel Blockers therapeutic class and recommended the following to the department by a unanimous vote:
  - CARDAMYST (NASAL) and SDAMLO SOLUTION (ORAL)to be to be added to the PDL as NONPREFERRED.
  - PROCARDIA (ORAL) to be removed from the PDL.

- The committee discussed the COPD Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - IPRATROPIUM BROMIDE HFA (INHALATION) and UMECLIDINIUM ELLIPTA (INHALATION) to be added to the PDL as NONPREFERRED.

- The committee discussed the Growth Hormone therapeutic class and recommended the following to the department by a unanimous vote:
  - GENOTROPIN CARTRIDGE (INJECTION) and GENOTROPIN DISP SYRIN (INJECTION) to be moved on the PDL to PREFERRED.
  - ZOMACTON VIAL (INJECTION) to be moved on the PDL to NONPREFERRED.
  - HUMATROPE CARTRIDGE (INJECTION) and HUMATROPE VIAL (INJECTION) to be removed from the PDL.

- The committee discussed the HAE Treatments therapeutic class and recommended the following to the department by a unanimous vote:
  - HAEGARDA (SUB-Q) to be moved on the PDL to PREFERRED.
  - CINRYZE (INTRAVEN) to be moved on the PDL to NONPREFERRED.

- The committee discussed the Ophthalmic Antibiotics therapeutic class and recommended the following to the department by a unanimous vote:
  - BESIFLOXACIN (OPHTHALMIC), LEVOFLOXACIN (OPHTHALMIC) and NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC) to be added to the PDL as NONPREFERRED.

- The committee discussed the Opiate Dependence Treatments therapeutic class and recommended the following to the department by a unanimous vote along with a call for DHS to continue to evaluate the addition of a long-acting preferred product:

- BUPRENORPHINE/NALOXONE FILM (SUBLINGUAL) and NALOXONE SPRAY OTC (NASAL) to be moved on the PDL to PREFERRED.
- REXTOVY SPRAY (NASAL) and SUBOXONE FILM (SUBLINGUAL) to be moved on the PDL to NONPREFERRED.
- REZENOPY SPRAY (NASAL) to be added to the PDL as NONPREFERRED.
- ZIMHI (INJECTION) to be removed from the PDL.

CONSENT AGENDA ITEMS:
The committee discussed and recommended by unanimous vote that these classes under the Consent Agenda Items be approved as presented:

- Anticonvulsants, Other
- Antifungals, Oral
- Antivirals, General
- Antivirals, Oral
- Antivirals, Topical
- Bone Resorption Suppression And Related Agents
- Fluoroquinolones, Oral
- Glucocorticoids, Inhaled
- Hepatitis B Agents
- Hepatitis C Agents
- Hypoglycemics, SGLT2
- Otic Antibiotics

Other Business

- Reminder that elections for DFC Chair and Vice-Chair for 2027 will be held at the next meeting.
- All communication pertaining to policy recommendations and suggestions for the DFC should be directed to the DFC mailbox, patient specific communication should be directed to the helpdesk.

Adjournment

- The meeting was adjourned at approximately 11:58 a.m. Central Time.